EP0617621A4 - Zentrale cholecystokininantagonisten mit pharmazeutischer wirksamkeit. - Google Patents

Zentrale cholecystokininantagonisten mit pharmazeutischer wirksamkeit.

Info

Publication number: EP0617621A4
Authority: EP; European Patent Office
Prior art keywords: pharmaceutical activity; cholecystokinin antagonists; central; central cholecystokinin; antagonists
Prior art date: 1991-12-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP92903432A

Other languages

English (en)

French (fr)

Other versions

EP0617621A1 (de

Inventor

David Christopher Horwell

John Hughes

Geoff Neil Woodruff

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Organon Pharma UK Ltd

Original Assignee

Merck Sharp and Dohme Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-12-20

Filing date

1991-12-20

Publication date

1995-04-05

1991-12-20 Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd

1991-12-20 Priority to EP96200242A priority Critical patent/EP0729752A2/de

1994-10-05 Publication of EP0617621A1 publication Critical patent/EP0617621A1/de

1995-04-05 Publication of EP0617621A4 publication Critical patent/EP0617621A4/de

Status Withdrawn legal-status Critical Current

Links

102100025841 Cholecystokinin Human genes 0.000 title 1
101800001982 Cholecystokinin Proteins 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
229940107137 cholecystokinin Drugs 0.000 title 1
IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

EP92903432A 1991-12-20 1991-12-20 Zentrale cholecystokininantagonisten mit pharmazeutischer wirksamkeit. Withdrawn EP0617621A4 (de)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
EP96200242A EP0729752A2 (de)	1991-12-20	1991-12-20	Zentrale Cholecystokininantagonisten mit pharmazeutischer Wirksamkeit

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US1991/009555 WO1993012791A1 (en)	1991-12-20	1991-12-20	Central cholecystokinin antagonists having pharmaceutical activity

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
EP96200242A Division EP0729752A2 (de)	1991-12-20	1991-12-20	Zentrale Cholecystokininantagonisten mit pharmazeutischer Wirksamkeit

Publications (2)

Publication Number	Publication Date
EP0617621A1 EP0617621A1 (de)	1994-10-05
EP0617621A4 true EP0617621A4 (de)	1995-04-05

Family

ID=22226062

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP92903432A Withdrawn EP0617621A4 (de)	1991-12-20	1991-12-20	Zentrale cholecystokininantagonisten mit pharmazeutischer wirksamkeit.

Country Status (3)

Country	Link
EP (1)	EP0617621A4 (de)
JP (1)	JPH07507993A (de)
WO (1)	WO1993012791A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT652871E (pt) *	1992-07-29	2002-03-28	Merck Sharp & Dohme	Derivados de benzodiazepina
FR2744362B1 (fr) *	1996-02-07	1998-02-27	Rhone Poulenc Rorer Sa	Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
FR2744361B1 (fr) *	1996-02-07	1998-02-27	Rhone Poulenc Rorer Sa	Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
FR2744363B1 (fr) *	1996-02-07	1998-02-27	Rhone Poulenc Rorer Sa	Application de derives de thiazolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
TW442449B (en)	1996-07-04	2001-06-23	Hoechst Ag	Process for preparing 1,2-dichloroethane by direct chlorination
CA2370141A1 (en)	1999-05-26	2000-12-07	James D. Rodgers	1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors
EP1749525A1 (de) *	2005-07-15	2007-02-07	Laboratorios Del Dr. Esteve, S.A.	Zusammensetzung enthaltend substituierte Pyrazoline und gegen Sucht wirksame Mittel
WO2007009691A2 (en) *	2005-07-15	2007-01-25	Laboratorios Del Dr. Esteve, S.A.	Combination of substituted pyrazolines and anti -addictive agent
US8247438B2 (en)	2008-02-27	2012-08-21	Neuropill, Inc.	Methods for treating schizophrenia
WO2012075456A1 (en)	2010-12-02	2012-06-07	Constellation Pharmaceuticals	Bromodomain inhibitors and uses thereof
AR084070A1 (es)	2010-12-02	2013-04-17	Constellation Pharmaceuticals Inc	Inhibidores del bromodominio y usos de los mismos
WO2012151512A2 (en)	2011-05-04	2012-11-08	Constellation Pharmaceuticals, Inc.	Bromodomain inhibitors and uses thereof
EP2721031B1 (de)	2011-06-17	2016-01-20	Constellation Pharmaceuticals, Inc.	Bromodomainhemmer und ihre verwendungen
TWI602820B (zh)	2012-06-06	2017-10-21	星宿藥物公司	溴域抑制劑及其用途
WO2013184878A1 (en)	2012-06-06	2013-12-12	Constellation Pharmaceuticals, Inc.	Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof
US9969747B2 (en)	2014-06-20	2018-05-15	Constellation Pharmaceuticals, Inc.	Crystalline forms of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0411668A2 (de) *	1989-08-04	1991-02-06	MERCK SHARP & DOHME LTD.	Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3663771A (en) *	1971-01-12	1972-05-16	Gulf & Western Industries	Distributor rotor with improved contact securing means
IE57892B1 (en) *	1984-06-25	1993-05-05	Rotta Research Lab	Glutamic and aspartic acid derivatives
US4820834A (en) *	1984-06-26	1989-04-11	Merck & Co., Inc.	Benzodiazepine analogs
IT1215169B (it) *	1985-12-17	1990-01-31	Rotta Research Lab	Derivati alchil ossigenati degli acidi glutammico ed aspartico ad attivita antagonista su polipeptidi bioattivi e procedimento per la loro preparazione
CA2032427A1 (en) *	1989-12-18	1991-06-19	Mark G. Bock	Benzodiazepines analogs
CA2032226A1 (en) *	1989-12-18	1991-06-19	Mark G. Bock	Benzodiazepine analogs

1991
- 1991-12-20 JP JP4503379A patent/JPH07507993A/ja active Pending
- 1991-12-20 WO PCT/US1991/009555 patent/WO1993012791A1/en not_active Application Discontinuation
- 1991-12-20 EP EP92903432A patent/EP0617621A4/de not_active Withdrawn

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0411668A2 (de) *	1989-08-04	1991-02-06	MERCK SHARP & DOHME LTD.	Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9312791A1 *

Also Published As

Publication number	Publication date
EP0617621A1 (de)	1994-10-05
JPH07507993A (ja)	1995-09-07
WO1993012791A1 (en)	1993-07-08

Legal Events

Date	Code	Title	Description
1994-08-19	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
1994-10-05	17P	Request for examination filed	Effective date: 19940609
1994-10-05	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE
1995-04-05	A4	Supplementary search report drawn up and despatched	Effective date: 19950210
1995-04-05	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE
1998-08-12	17Q	First examination report despatched	Effective date: 19980630
1999-03-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
1999-05-06	18D	Application deemed to be withdrawn	Effective date: 19981111

Publication	Publication Date	Title
GR3018318T3 (en)	1996-03-31	Pharmaceutical agents.
PL297747A1 (en)	1993-11-02	Prolonged action pharmaceutical dosage forms
PH31205A (en)	1998-05-05	Pharmaceutical composition.
EP0670716A4 (de)	1996-10-02	Geschmacksmaskierte pharmazeutische substanzen.
ZA926020B (en)	1993-03-10	Pharmaceutical combination formulation.
GR3036937T3 (en)	2002-01-31	Pharmaceutical formulations.
ZA92600B (en)	1992-10-28	Lhrh antagonists
GR3032366T3 (en)	2000-04-27	Pharmaceutical cyclosporin composition.
EP0673247A4 (de)	1996-05-01	Fibrinogen rezeptor antagonisten.
EP0667773A4 (de)	1996-09-25	Fibrinogen-rezeptor-antagonisten.
FI921060A0 (fi)	1992-03-11	Farmaceutiska aerosolformuleringar.
FI922252A0 (fi)	1992-05-18	Farmaceutisk sammansaettning.
ZA927562B (en)	1993-04-14	Medicament.
EP0617621A4 (de)	1995-04-05	Zentrale cholecystokininantagonisten mit pharmazeutischer wirksamkeit.
ZA9110018B (en)	1993-06-21	2-acylamido derivatives of 3,4-dihydro-3-oxo-quinoxaline having pharmaceutical activity.
OA09810A (en)	1994-04-15	Pharmaceutical composition.
ZA92110B (en)	1993-07-08	Pharmaceutical compositions.
GB9202377D0 (en)	1992-03-18	Pharmaceutical agent
ZA927506B (en)	1993-05-03	New drug formulation.
AU113462S (en)	1992-03-13	Dosage center
EP0600754A3 (de)	1995-05-24	Pharmazeutische Infusionseinrichtung mit konstantem Durchfluss.
ZA927369B (en)	1993-06-18	Pharmaceutical compositions.
ZA939626B (en)	1994-08-18	Pharmaceutical compounds.
ZA922586B (en)	1993-03-31	Cholecystokinin antagonists
ZA929916B (en)	1993-06-23	Therapeutic agents.